PDL BioPharma Announces Upcoming Changes to its Board of Directors
Ms. O'Farrell said, "I am excited to serve as Chairperson at this critical time in PDL's history and look forward to working with my fellow directors and the management team to unlock the value of our portfolio for our shareholders. We believe these changes are another step in the process as the Board will be more appropriately sized for our value maximization process. On behalf of the Board, I would like to thank Barry and Paul for their long service to PDL and much valued contributions. We wish them all the best going forward."
Ms. O'Farrell joined PDL's Board in
Dr. Selick said, "It has been an honor to serve as PDL's Chairperson. I am very proud of our Company's accomplishments throughout its history. PDL has made possible transformative scientific innovations and the development of life-changing therapies. I am completely aligned with the recent actions taken by the Company and have every confidence in the Board and management team's ability to maximize the value of PDL's assets for our shareholders."
In conjunction with these changes to PDL's Board,
Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies.
For more information please visit www.pdl.com.
This press release contains certain forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. The Company is subject to risks and uncertainties described in the Company's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis and expectations only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly release the results of any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-announces-upcoming-changes-to-its-board-of-directors-300977343.html
Investors: Dominique Monnet, PDL BioPharma President & CEO, 775-832-8500, Dominique.Monnet@pdl.com; LHA Investor Relations, Jody Cain, SVP, 310-691-7100, email@example.com; Okapi Partners, Mark Harnett, 212-297-0720; Media: Reevemark, Renée Soto / Hugh Burns / Nicholas Leasure, 212-433-4600